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Abstract
Phosphorylation of epidermal growth factor receptor (EGFR) on tyrosine 845 by c-Src has been shown to be important
for cell proliferation and migration in several model systems. This cross talk between EGFR and Src family kinases
(SFKs) is one mechanism for resistance to EGFR inhibitors both in cell models and in the clinic. Here, we show that
phosphorylation of tyrosine 845 on EGFR is required for proliferation and transformation using several cell models of
breast cancer. Overexpression of EGFR-Y845F or treating cells with the SFK inhibitor dasatinib abrogated tyrosine
845 phosphorylation, yet had little to no effect on other EGFR phosphorylation sites or EGFR kinase activity. Abroga-
tion of Y845 phosphorylation inhibited cell proliferation and transformation, even though extracellular signal-regulated
kinase (ERK) and Akt remained active under these conditions. Importantly, cotransfection ofmitogen-activated protein
kinase (MAPK) kinase 3 and p38 MAPK restored cell proliferation in the absence of EGFR tyrosine 845 phosphoryla-
tion. Taken together, these data demonstrate a novel role for p38 MAPK signaling downstream of EGFR tyrosine 845
phosphorylation in the regulation of breast cancer cell proliferation and transformation and implicate SFK inhibitors as
a potential therapeutic mechanism for overcoming EGFR tyrosine kinase inhibitor resistance in breast cancer.
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Introduction
The epidermal growth factor receptor (EGFR) is a tyrosine kinase re-
ceptor identified as an oncogene in many types of solid tumors. Small-
molecule inhibitors as well as monoclonal inhibitory antibodies have
demonstrated clinical efficacy in a number of tumor types, including
lung, colon, and pancreatic cancers (reviewed in [1]). Thirty percent
of breast cancers overexpress EGFR and this overexpression correlates
with poor prognosis [2–4]. However, studies have yet to show an
efficacy for EGFR inhibition in breast cancer [5,6]. Mechanisms of
resistance to EGFR inhibitors, either intrinsic or acquired, have been
characterized in lung, colon, brain, and pancreatic tumors to involve
the activation of other tyrosine kinases including Met and c-Src
(reviewed in [1,7,8]). In breast cancer models, we have found that both
Met and c-Src are mediators of EGFR inhibitor resistance [9,10].
EGFR and c-Src have been shown to functionally interact in several
model systems including human mammary epithelial cells [11,12].
Specifically, ectopic expression of both EGFR and c-Src resulted in
synergistic increases in proliferation, transformation, and tumorigenesis.
The mechanism for this synergy is currently unknown; however, it was
demonstrated that under the synergistic conditions two tyrosines in the
intracellular domain of the EGFR were phosphorylated, namely, tyro-
sines 845 and 1101 [13]. EGFR tyrosine 845 is particularly interesting
because of its location within the activation loop of the kinase domain of
the EGFR. This tyrosine is highly homologous to autophosphorylated
tyrosines found in the kinase domains of other tyrosine kinases [14],
which have been shown to be critical to their activation. However,
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unlike the tyrosines in these other kinases, EGFR tyrosine 845 is not an
autophosphorylation site and does not need to be tyrosine phosphory-
lated for the kinase to be active [13]. Instead, phosphorylation of EGFR
tyrosine 845 is a direct substrate of Src [13]. Mutating this tyrosine to
a nonphosphorylatable phenylalanine (Y845F) and subsequent ex-
pression in fibroblasts lead to an abrogation of EGF-induced DNA syn-
thesis, even though receptor autophosphorylation, phosphorylation of
EGFR substrates such as Shc, and downstream ERK activation are
unaffected [13]. Taken together, these data suggest that tyrosine
845 phosphorylation is critical to the EGFR/c-Src biologic synergy
and cross talk. Therefore, the identification of Y845-dependent signal-
ing pathways is not only important to understand EGFR signaling but
also important to the development of therapeutic interventions that
disrupt the synergistic affects of EGFR and Src.
Here, we demonstrate that phosphorylation of Y845 on EGFR is
required for cell growth and transformation in breast cancer cell lines.
In addition, we show that EGFR remains tyrosine phosphorylated on
all five autophosphorylation sites and is kinase active when tyrosine
845 phosphorylation is inhibited by either mutation to phenylalanine or
treatment of cells with the Src family kinase (SFK) inhibitor dasatinib.
Under either condition, EGFR was autophosphorylated and stimulated
signaling through the Ras/MAPK and phosphomositide 3-kinase (PI3
kinase)/Akt pathways. Interestingly, p38 MAPK activity was inhibited
upon loss of EGFR tyrosine 845 phosphorylation. Upstream of p38
MAPK phosphorylation, Gab1 phosphorylation was reduced, whereas
Shc remained phosphorylated. Significantly, the decrease in cell prolif-
eration because of the loss of EGFR tyrosine 845 phosphorylation
could be overcome by ectopic coexpression of p38 MAPK and a con-
stitutively active MAP kinase kinase 3 (MKK3), its direct activator.
Taken together, these data suggest that Src synergism with EGFR occurs
through Gab1 and p38 MAPK signaling pathway to enhance cell pro-
liferation and transformation in breast cancer cells.
Materials and Methods
Reagents
Dasatinib was purchased from LC Laboratories (Woburn, MA).
Doxycycline and EGF, as well as tissue culture supplements, were pur-
chased from Sigma (St Louis, MO). Other reagents were purchased
from Thermo Fisher (Pittsburgh, PA).
Cell Models and Transfections
MCF7 cells inducibly expressing wild-type (wt)–EGFR or the
EGFR tyrosine 845 phenylalanine mutant were generated previously
[15]. SUM149 cells are a triple-negative breast cancer cell line from a
patient with inflammatory breast cancer and are a gift from Dr Stephen
Ethier (Medical University of South Carolina, Charleston, SC).
Constitutively active MKK3 (MKK3EE) and p38 MAPK in pcDNA
were provided by Roger Davis (University of Massachusetts) [16]. The
p38 MAPK construct was FLAG-tagged as described previously [17].
Transfections into SUM149 cells were performed using FuGENE 6
according to the manufacturer’s recommendations (Roche Applied
Sciences, Indianapolis, IN).
Cell Proliferation Assays
Cells were plated at 35,000 cells/well in a six-well dish on day 0.
On day 1, cells were either induced to express the EGFR constructs
with 1 mg/ml doxycycline. The cells were treated every other day with
0, 0.1, 0.5, or 1 μM dasatinib for 8 days. For the transfection exper-
iments, cells were transfected with wt-EGFR or Y845F-EGFR on
day 1 and again on day 4. The number of cells present at day 4 and
day 8 or 9 was measured using a Coulter counter. Each experiment was
performed in triplicate at least three times. Statistics were performed
using Student’s t test.
Soft Agar Colony Formation Assays
Soft agar plates were prepared with a 0.5% agar bottom layer, a
0.45% agar cell layer, and a 0.35% top layer. One day after seeding,
cells were treated with 1 mg/ml doxycycline or 0.5 μMdasatinib every
other day with the addition of fresh media for 3 weeks. Colonies
greater than 50 cells in size were counted on a microscope and nor-
malized to the DMSO-treated control, which was set at 100% colony
formation. Experiments were performed in triplicate at least three
times. Student’s t test was used to determine statistical significance.
Immunoprecipitation and Immunoblot analysis
Cells were lysed in CHAPS lysis buffer (10 mM CHAPS, 50 mM
Tris (pH 8.0), 150 mMNaCl, and 2 mM EDTA with 10 μMNaOVa
and 1× protease inhibitor cocktail (EMD Biosciences, Rockland, MA).
For the immunoprecipitation assays, 0.5 mg of protein was used for
immunoprecipitation using anti-EGFR antibodies (mab108,M.Weber,
University of Virginia, Charlottesville, VA). Antibody-bound proteins
were collected using 40 μl of protein A beads (Millipore, Billerica, MA)
and washed three times with phosphate-buffered saline (PBS). Immuno-
blot analysis was performed after sodium dodecyl sulfate (SDS)–
polyacrylamide gel electrophoresis (PAGE) and transfer to polyvinylidene
fluoride (PVDF) membranes. Membranes were blocked in either 5%
nonfat dry milk or BSA depending on the recommendations of the
antibody manufacturer. Primary antibodies used in this study include
EGFR, pY845 EGFR, pY992 EGFR, pY1068 EGFR, pY1086 EGFR,
pY1148 EGFR, pY1173 EGFR, GRB2-associated binding protein 1
(Gab1), phospho-Gab1 (pGab1), Akt, phospho-Akt (pAkt), ERK,
p38 MAPK, and phospho-p38 (pp38) MAPK from Cell Signaling
(Danvers, MA); actin and FLAG from Sigma; phospho-ERK (pERK)
and phospho-Src (pSrc) from Invitrogen (Carlsbad, CA); and Src (2–17;
Dr Sally Parsons, University of Virginia). Anti-mouse and anti-rabbit
IgG-HRP were used from Cell Signaling, and enhanced chemilumi-
nescence reagents were fromGEHealthcare Life Sciences (Piscataway, NJ).
In Vitro Kinase Assays
Stable MCF7 cells were induced to express wt-EGFR or Y845F-
EGFR with doxycycline for 48 hours. Cells were then serum starved
for 24 hours and stimulated with 10 ng/ml EGF for 15 minutes.
Cells were washed twice in PBS and lysed in solubilization buffer
[50 mM HEPES (pH 7.5), 10% glycerol, 0.5% Triton X-100, 1.5 mM
MgCl2, 1 mM EGTA, 1 mM polymethylsufonyl fluoride, 50 μg/ml
aprotinin, and 400 nM sodium orthovanadate]. Lysates were cleared
by centrifugation, protein concentration was determined by the Bio-
Rad Bradford Assay (Hercules, CA), and 0.5 mg of protein was used
for an immunoprecipitation using anti-EGFR antibody mab108.
Antibody-bound proteins were collected using 40 μl of protein A beads
(Millipore) and washed three times in HTG buffer (20 mM HEPES
(pH 7.5), 0.1% Triton X-100, and 10% glycerol). For the kinase assay,
40 μl of HTG buffer, 4 μl of MnCl2 (of 100 mM stock), and 10 μCi
32P-γATP were incubated with the immunoprecipitates for 10 minutes
at 30°C. The beads were pelleted, and the supernatant was removed
and discarded. The beads were washed twice with solubilization buffer
and once with PBS. Forty microliters of sample buffer was added to the
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pellets, the samples were boiled, and proteins were separated using
7.5% SDS-PAGE. The gels were dried and exposed to film. Each ex-
periment was repeated at least three times.
Rac Activity Assays
MCF7 or SUM149 cells were treated as indicated and lysed accord-
ing to the manufacturer’s recommendations (Millipore). Briefly, 10 μl
of PAK-1 p21 binding domain (PBD) agarose was added to 500 μg of
protein lysate for 1 hour at 4°C. Precipitates were washed three times with
lysis buffer, and the pellet was resuspended in 2× sample buffer. Proteins
were separated by SDS-PAGE and transferred to membranes. Immuno-
blots were performed using an anti–Rac-1 antibody. Positive and negative
controls provided by the manufacturer were used (GTPγS or guanosine
diphosphate [GDP]). Each experiment was repeated at least three times.
BrdU Incorporation Assays
MCF7 cells inducibly expressing wt-EGFR or Y845F-EGFR and
SUM149 cells were transfected with constitutively active MKK3 and
p38 MAPK in a ratio of 1:5. For the MCF7 models, cells were induced
to express wt-EGFR or Y845F-EGFR at the time of plating on cover-
slips and transfected 24 hours later. SUM149 cells were plated and,
24 hours later, treated with 0.5 μM dasatinib and transfected. After
transfection for 24 hours, bromodeoxyuridine (BrdU; Invitrogen)
was added to the cells for 4 hours. Cells were then fixed and stained
for BrdU incorporation as well as for the FLAG tag on the transfected
vectors using fluorescent-tagged antibodies (Invitrogen). Transfected
cells were counted to determine the percent BrdU positive. Each exper-
iment was repeated at least three times in duplicate. Student’s t test was
used to determine statistical significance.
Results
EGFR Tyrosine 845 Phosphorylation Is Required for
Transformation of Breast Cancer Cells
We have previously shown that inhibiting phosphorylation of
tyrosine 845 on EGFR decreases DNA synthesis [11,12,15]. Using
an MCF7 cell model engineered to inducibly express either wt-EGFR
or a tyrosine to phenylalanine mutant at tyrosine 845 (Y845F-EGFR;
Figure 1B), we sought to determine if EGFR tyrosine 845 phosphor-
ylation regulated the ability of cells to grow in soft agar. As MCF7
cells express less than 10,000 EGFR molecules per cell, using these
models will allow us to test the role of tyrosine 845 phosphorylation
with little contribution of endogenous EGFR [18]. MCF7 cells induced
to express wt-EGFR increased soft agar colony formation by 80% com-
pared to the uninduced controls (Figure 1A, black bars + Dox), similar
to the results obtained upon EGFR and c-Src co-overexpression in
fibroblasts or mammary epithelial cells [11,12]. In contrast, expression
of the Y845F-EGFR mutant abrogated this increase in soft agar colony
formation, essentially inhibiting the biologic synergy that occurs with
EGFR and c-Src co-overexpression (Figure 1A, white bars + Dox).
Without inducing expression of wt-EGFR or Y845F-EGFR with doxy-
cycline, both cell lines showed a similar increase in colony formation
with EGF stimulation (Figure 1A). These results demonstrate for
the first time that the phosphorylation of a single site on EGFR may
regulate cellular transformation.
Previously, EGFR kinase activity has been shown to be required
for proliferation in the SUM149 breast cancer cell line in which both
EGFR and c-Src are overexpressed [9,19,20]. To support the data from
the inducible MCF7 cell model, we transiently transfected Y845F-
EGFR into SUM149 breast cancer cells and measured cell prolifer-
ation. Importantly, transient expression of Y845F-EGFR completely
abrogated SUM149 cell proliferation (Figure 2A). This loss of cell pro-
liferation is comparable to treatment of SUM149 cells with 1.0 μM
gefitinib, a selective EGFR inhibitor [9]. At the time of plating for
the proliferation assay, lysates were made from the remaining cells to
verify EGFR overexpression and loss of EGFR tyrosine 845 phosphor-
ylation (Figure 2B). As a control, transient overexpression of wt-EGFR
resulted in constitutive phosphorylation of EGFR tyrosine 845 as well
as EGFR tyrosine 1068 and tyrosine 1173, two EGFR autophosphor-
ylation sites (Figure 2B). However, in Y845F-EGFR–expressing cells,
EGF-induced EGFR tyrosine 845 phosphorylation was reduced com-
pared to wt-EGFR, whereas EGFR tyrosine 1068 and tyrosine 1173
phosphorylation were unaffected (Figure 2B). The EGF-inducible
EGFR tyrosine phosphorylation in the Y845F-EGFR–transfected cells
Figure 1.Mutation of tyrosine 845 to phenylalanine on EGFR inhibits cellular transformation. (A) MCF7 cells were induced to express
wt-EGFR (WT) or Y845F-EGFR (Y845F) with 1 mg/ml doxycycline (Dox) in the presence or absence of EGF while plated in soft agar to
measure transformation. Doxycycline was added every other day for 3 weeks of the transformation assay. (B) MCF7 cells were induced to
express wt-EGFR or Y845F-EGFR with 1 mg/ml doxycycline for 48 hours and lysed. Lysates were immunoblotted using anti-EGFR and
anti–β-actin antibodies. P values were calculated using Student’s t test. EGF, *P = .0316, +P = .0064. Each experiment was performed
in triplicate at least three times.
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represents the phosphorylation of endogenous EGFR. These data
suggest that inhibition of EGFR tyrosine 845 phosphorylation by
transfection of the Y845F-EGFR acts as a dominant negative with
respect to proliferation.
Tyrosine 845 on EGFR is not an autophosphorylation site and
instead is phosphorylated by SFKs. We have previously shown that
inhibiting SFK activity with the SFK inhibitor PP2 or a dominant
negative c-Src in SUM149 cells abrogates cell proliferation and
DNA synthesis [9]. Using a more clinically relevant SFK inhibitor,
dasatinib, we wanted to determine the importance of SFK activity to
the proliferation of SUM149 cells. By performing cell counts, 100 nM
dasatinib was shown to be sufficient to block SUM149 cell proliferation
(Figure 3A). These results demonstrate that inhibition of SFK activity
in a breast cancer cell line with EGFR and c-Src co-overexpression is
sufficient to abrogate cell proliferation.
Using lysates from SUM149 cells treated with dasatinib, we
measured the ability of SFK inhibition to abrogate EGFR tyrosine
845 phosphorylation. Dasatinib treatment inhibited Src autophosphor-
ylation on tyrosine 418 and EGFR tyrosine 845 phosphorylation
(Figure 3B). However, similar to the results with transient transfection
of Y845F-EGFR, phosphorylation of EGFR Y1086 and Y1173 was
unaffected by dasatinib treatment. Therefore, inhibition of SFK ac-
tivity blocked EGFR tyrosine 845 phosphorylation without altering
autophosphorylation of EGFR. These results again support the
Figure 3. Inhibition of EGFR tyrosine 845 phosphorylation using dasatinib decreased cell growth and transformation. (A) SUM149 cells
were plated on day 0, and dasatinib was added at 0.1, 0.5, or 1.0 μMonday 1 and every other day for 8 days. Cells were counted on days 1, 4,
and 8. (B) SUM149 cells were treated with 0.5 μM dasatinib for 2 hours and 10 ng/ml EGF for 15 minutes. Cell lysates were prepared,
separated by SDS-PAGE, and immunoblotted using pY845-EGFR, EGFR, pSrc, Src, actin, pY1173-EGFR, and pY1086-EGFR antibodies.
(C) SUM149 cells were seeded in soft agar and treated with 0.5 μM dasatinib every other day for 3 weeks. UT = DMSO vehicle control.
P value was calculated using Student’s t test. *P = .0031. Growth and transformation assays were performed in triplicate at least three
times. Immunoblot analysis was performed in at least three separate experiments.
Figure 2. Transient expression of Y845F-EGFR decreases cell proliferation. (A) SUM149 cells were transiently transfected with Y845F-
EGFR on day 0, and cells were counted on days 1, 2, and 4. (B) Cell lysates were prepared from companion plates transfected with the
growth assay and cultured for 4 days of the growth assays. Equal protein was separated by SDS-PAGE and was immunoblotted using
EGFR, pY845-EGFR, pY1068-EGFR, pY1173-EGFR, and actin antibodies. Cell proliferation assays were performed in triplicate at least
three times, and immunoblot analysis was performed at least three times. UT = pcDNA3 transfected.
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hypothesis that inhibition of cell proliferation by loss of EGFR
tyrosine 845 phosphorylation occurs independent of changes to
EGFR autophosphorylation.
To determine if dasatinib inhibition of EGFR tyrosine 845 phos-
phorylation decreased cellular transformation, SUM149 cells were
plated in soft agar and treated with 0.5 μM dasatinib every other
day for 3 weeks. Dasatinib treatment decreased soft agar colony num-
ber by 40% compared to DMSO-treated controls (Figure 3C ). Taken
together, these results provide evidence for a role for EGFR and SFK
cross talk in SUM149 cells to mediate proliferation and transforma-
tion through phosphorylation of EGFR tyrosine 845.
Loss of EGFR Tyrosine 845 Phosphorylation Does Not Alter
EGFR Autophosphorylation or Kinase Activity
Tyrosine 845 on EGFR is a conserved tyrosine found in all tyrosine
kinases located within the activation loop of the kinase domain [13].
In contrast to other tyrosine kinases, tyrosine 845 on EGFR is not
required for its kinase activity [13]. Therefore, we would predict that
inhibiting EGFR tyrosine 845 phosphorylation in the MCF7 cell
models would not change autophosphorylation or kinase activity of
EGFR. Indeed, all five EGFR autophosphorylation sites remained
phosphorylated and EGFR kinase activity was maintained when
Y845F-EGFR was expressed in MCF7 cells (see Figure W1). Simi-
larly, transient expression of Y845F-EGFR in SUM149 cells did
not abrogate phosphorylation of EGFR autophosphorylation site
tyrosine 1068 (Figure 2B) and dasatinib did not inhibit phosphory-
lation of tyrosine 1086 (Figure 3C ). Taken together, these data sup-
port that although phosphorylation of tyrosine 845 on EGFR is
required for cell proliferation, DNA synthesis, and transformation
in these breast cancer cell models, it is not required for autophosphor-
ylation or kinase activity of EGFR. Therefore, inhibition of EGFR
tyrosine 845 phosphorylation is sufficient to decrease cell prolifera-
tion, DNA synthesis, and transformation in the context of fully acti-
vated and phosphorylated EGFR.
Loss of EGFR Tyrosine 845 Phosphorylation Reduces Gab1
and p38 MAPK Phosphorylation
To understand what signaling pathways are being inhibited when
EGFR tyrosine 845 phosphorylation is lost, we examined a panel of
key EGFR signaling proteins, including Akt and the MAP kinases
ERK and p38 MAPK. Interestingly, ERK and Akt remained phos-
phorylated when EGFR tyrosine 845 phosphorylation was abrogated
by dasatinib treatment, whereas expression of Y845F-EGFR decreased
Akt phosphorylation but not ERK phosphorylation (Figures 4, A and
B, and W2). In contrast, the phosphorylation of the stress-associated
MAPK, p38 MAPK, was lost under both basal and EGF-stimulated
conditions (Figures 4, A and B, and W2). These data suggest that
in the absence of endogenous EGFR in the MCF7 cells, signaling
from Y845-EGFR phosphorylation is mediated downstream by
both Akt and p38 MAPK phosphorylation. However, in the context
of endogenous EGFR, Y845-EGFR phosphorylation is required for
p38 MAPK activation.
Phosphorylation of p38 MAPK has been shown to occur down-
stream of EGFR signaling through a Gab1/Rac-mediated pathway
[21]. Therefore, we tested the phosphorylation status of Gab1 in the
absence of EGFR tyrosine 845 phosphorylation. As predicted, Gab1
phosphorylation was reduced when EGFR tyrosine 845 phosphory-
lation was prevented (Figures 4, A and B, and W2). However, co-
immunoprecipitation assays demonstrated that the association of
Gab1 with EGFR remained unaltered (Figure 5A). These data are
not surprising in that Gab1 has been shown to associate with EGFR
through other phosphorylated tyrosines [22]. In addition, we tested
the role of Rac1 activity in models of EGFR tyrosine 845 phosphory-
lation, as Rac1 has been shown to be a mediator between Gab1 and
Figure 4. Signaling through Akt and MAPK but not p38 MAPK is maintained in the absence of EGFR tyrosine 845 phosphorylation.
(A) MCF7 cells induced to express wt-EGFR or Y845F-EGFR or (B) SUM149 cells treated with dasatinib for 2 hours were treated with
10 ng/ml EGF for 15 minutes. Cell lysates were made, and subsequent separated protein was immunoblotted using pGab1-Tyr627,
Gab1, pAkt-Ser473, Akt, pMAPK-Thr185/Tyr187, MAPK, pp38 MAPK–Thr180/Tyr182, and p38 MAPK antibodies. Each experiment
was performed at least three independent times.
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p38 MAPK signaling. However, Rac1 was not activated either basally
or in the presence of EGF in either the MCF7 or the SUM149 cell
model (Figure 5B), suggesting an alternative mediator for Gab1/p38
MAPK signaling.
Constitutive Activation of p38 MAPK Restores Proliferation
in the Absence of EGFR Tyrosine 845 Phosphorylation
To determine if p38 MAPK phosphorylation is a signaling link
between EGFR tyrosine 845 phosphorylation and proliferation, we
Figure 5. Gab1/Rac signaling is not mediating p38 MAPK activity. (A) MCF7 cells induced to express either wt-EGFR or Y845F-EGFR
were treated with EGF for 15 minutes. Lysates were prepared and immunoprecipitated with anti-EGFR antibodies. Immunoprecipitates
were washed and separated by SDS-PAGE. Immunoblot analysis using EGFR or Gab1 antibodies was performed. (B) MCF7 cells were
induced to express either wt-EGFR or Y845F-EGFR, or SUM149 cells were treated with 0.5 μM dasatinib for 2 hours. Cells were stim-
ulated with 10 ng/ml EGF for 15 minutes. Lysates were prepared using MLB lysis buffer provided by the manufacturer. Activated Rac
was isolated from the lysates using the Rac-binding domain from PAK-1 (PAK BD). GTPγS (+C) or GDP (−C) was added to two of the
SUM149 lysate reactions for positive and negative controls. In addition, whole-cell lysates were run next to the immunoprecipitations for
expression controls. After gel electrophoresis, immunoblot analysis was performed using Rac antibodies. Each experiment was repeated
at least three times.
Figure 6. p38 MAPK activity compensates for loss of tyrosine 845 phosphorylation on EGFR. (A) MCF7 inducibly expressing wt-EGFR or
Y845F-EGFR and SUM149 were transfected with MKK3EE and FLAG-tagged p38 MAPK at a 1:5 ratio. Lysates were collected, and immuno-
blot analysis was performed using anti-FLAG and anti–β-actin antibodies. (B) MCF7 cells induced to express wt-EGFR or Y845F-EGFR and
(C) SUM149 cells were transfected with constitutively active MKK3EE and p38 MAPK on coverslips for 48 hours. A 4-hour BrdU pulse was
followed by cell fixation and staining using anti-BrdU fluorescent antibodies and anti-FLAG followed by anti-mouse fluorescent antibodies.
FLAG-positive cells were determined to be BrdU positive or negative. Untransfected wt-EGFR MCF7 cells (A) and untransfected, untreated
SUM149 cells (B) were used as 100% BrdU-positive controls. Student’s t test was used to identify statistical significance. Each experiment
was repeated three times in duplicate. Student’s t test was used to calculate P values. MCF7 cells, *P= .0005 and SUM149 cells, *P= .013.
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transiently cotransfected an activated form of MKK3, a direct activa-
tor of p38 MAPK, with a FLAG-tagged p38 MAPK into MCF7 and
SUM149 cells (Figure 6A). We induced either wt-EGFR or Y845F-
EGFR expression with doxycycline at the time of MKK3/p38
MAPK transfection, waited 48 hours, and measured BrdU incor-
poration in cells positive for FLAG–p38 MAPK (Figure 6B). Impor-
tantly, activation of p38 MAPK with the constitutively active MKK3
increased BrdU incorporation four-fold in MCF7 cells expressing
Y845F-EGFR. Similarly, dasatinib-treated SUM149 cells showed a sig-
nificant increased in DNA synthesis when p38 MAPK was activated
(Figure 6C ). Taken together, these data provide strong evidence for
p38 MAPK activity as being a downstream mediator of EGFR tyrosine
845 phosphorylation required for proliferation and transformation.
Discussion
From these studies, we have identified p38 MAPK activation as a key
event in the synergistic signaling between EGFR tyrosine 845 phos-
phorylation and Src. Specifically, we demonstrated that loss of EGFR
tyrosine 845 phosphorylation, either by mutation or kinase inhibi-
tion of SFKs, dramatically decreased cell growth and transformation.
This loss of EGFR tyrosine 845 phosphorylation resulted in decreased
p38 MAPK phosphorylation, with a decrease in Akt phosphorylation
in the MCF7 cells expressing low levels of endogenous EGFR. Inter-
estingly, constitutive activation of p38 MAPK in the presence of the
EGFR tyrosine 845 to phenylalanine mutation or the SFK inhibitor
dasatinib rescued proliferation. Taken together, these data provide
strong evidence for the co-overexpression of EGFR and SFKs and
the subsequent phosphorylation of EGFR tyrosine 845 in prolifera-
tion and transformation mediated by p38 MAPK activation.
The role of p38 MAPK in cancer has been thought to occur through
negative regulation of the cell cycle and senescence, suggesting that
p38 MAPK is a tumor suppressor gene [23]. In addition, p38 MAPK
activation in response to chemotherapy has been thought to work as a
mechanism for inducing apoptosis (reviewed in [24]). These data imply
that loss and inactivation of p38 MAPK would mediate tumor growth
and survival. However, our data demonstrate that in the context of
EGFR and c-Src coexpression, p38MAPK activation regulates cell pro-
liferation and anchorage-independent growth. In support of our stud-
ies, activation of p38 MAPK has been shown to stimulate proliferation
in response to specific stimuli including DNA damage, osmotic stress,
and inflammation [25]. In addition, p38 MAPK activity was found
to be upregulated in breast, head and neck, lymphoma, glioma, and
squamous cell carcinomas (reviewed in [26]). Specifically, phosphory-
lation of p38 MAPK was found to be a negative prognostic indicator
in human epidermal growth factor receptor 2 (HER2)-negative, lymph
node–positive breast cancers [27]. A number of p38 MAPK inhibitors
are in Phase I and II clinical trials (reviewed in [26]).
Although p38MAPK is often considered as a stress-induced kinase,
EGFR signaling has been shown to mediate p38 MAPK activation.
One mechanism by which EGFR activates p38 MAPK signaling is
through c-Src [28]. Src is directly activated by EGFR, phosphorylating
c-Src on tyrosine 416/418. As discussed above, EGFR and c-Src when
expressed at high levels stimulate the activation of synergistic signaling
pathways [11,12]. Mikami et al. found that Src phosphorylates MKK3
and MKK6, the kinases that phosphorylate and activate p38 MAPK
[28]. Our data demonstrate that when EGFR and c-Src are expressed
and activated in our breast cancer models, p38 MAPK is activated.
Yet, when EGFR and c-Src cross talk is eliminated by loss of EGFR
tyrosine 845 phosphorylation, either by mutation or Src kinase inhibi-
tion, p38MAPK phosphorylation is abrogated. This loss of p38MAPK
phosphorylation correlates with a decrease in proliferation. Signifi-
cantly, introducing a constitutively active MKK3 to induce p38MAPK
phosphorylation was sufficient to reverse the reduction in phosphory-
lation when EGFR tyrosine 845 phosphorylation was inhibited. There-
fore, we have established a novel link between EGFR and c-Src cross
talk and proliferation through p38 MAPK phosphorylation.
Resistance to targeted therapies, such as EGFR inhibitors, in the
clinic has become a significant challenge in the treatment of cancer.
Identifying biomarkers and characterizing activated signaling pathways
will improve the selection of the best targeted therapies for patients.
Here, we have shown in breast cancer cells that phosphorylation of
EGFR on tyrosine 845 by SFK is critical to the proliferation and trans-
formation of these cells. In addition, activation of p38 MAPK over-
came the need for EGFR tyrosine 845 phosphorylation. Therefore,
EGFR tyrosine 845 phosphorylation may be a good biomarker for
SFK inhibitor therapy.
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Figure W1. EGFR remains phosphorylated in the absence of EGFR
tyrosine 845 phosphorylation. MCF7 cells were induced to ex-
press wt-EGFR or Y845F-EGFR for 48 hours. Cells were placed in
serum-free media for 24 hours and stimulated with 10 ng/ml EGF
for 5 minutes. Lysates were prepared, and protein was separated
by SDS-PAGE and immunoblotted using pY845-EGFR, pY992-
EGFR, pY1068-EGFR, pY1086-EGFR, pY1148-EGFR, pY1173-EGFR,
and EGFR antibodies. Additionally, lysates were immunoprecipitated
using EGFR antibodies and in vitro kinase assays were performed to
measure incorporation of phosphate into EGFR.
Figure W2. Quantification of phospho-immunoblots. Immunoblots were scanned, and the appropriate regions were isolated using
Adobe Photoshop. AlphaEaseFC was used to quantify the digitized images. To compare between experiments, we set EGF-treated
wt-EGFR or no dasatinib values to 1.0. The relative densitometric values for each phosphorylated protein were divided by the protein
expression values. The representative numbers are the average of at least three experiments. Student’s t test was used to calculate the
P values. (A) WT + EGF versus Y845F + EGF: pAkt/Akt, *P = .0488; pp38 MAPK/p38 MAPK, *P = .0229; pGab1/Gab1, *P = .0359.
(B) EGF versus Das + EGF: pp38 MAPK/p38 MAPK, *P = .0022; pGab1/Gab1, *P = .05.
